HNC364 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05523570
(ClinicalTrials.gov)
August 22, 202224/8/2022A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable SuspensionPhase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable SuspensionParkinson's DiseaseDrug: HNC364Guangzhou Henovcom Bioscience Co. Ltd.NULLRecruiting18 Years45 YearsAll18Phase 1United States